Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).